Press Release: Rarecells, Inc. Appoints Dr. Neil Kurtz to Board of Directors
NEW YORK – (March 26, 2025) – Rarecells, Inc., a pioneering company in liquid biopsy, is pleased to announce the appointment of Dr. Neil Kurtz to its Board of Directors.
Latest news
To find out about what Rarecells is doing around the globe explore our featured news or contact our team at newsroom@rarecells.com.
Featured news
Press Release: Rarecells, Inc. Appoints Dr. Neil Kurtz to Board of Directors
NEW YORK – (March 26, 2025) – Rarecells, Inc., a pioneering company in liquid
Press Release: Rarecells announces Appointment of New Director to the Board
NEW YORK, Sept. 6, 2022 /PRNewswire/ — Rarecells, Inc. today announced the appointment of Dr. Neil Gunn,
Press release : Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests
NEW YORK and PARIS, Dec. 9, 2021 — Rarecells, Inc., an innovative Liquid Biopsy
Press release : Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)
New York, November 9th, 2021 — Rarecells, Inc., a healthcare company in the field
Prof. Patrizia Paterlini-Brechot – Rarecells, Inc. – embarks on the search for the First Cell to beat cancer
We are delighted to join the prestigious The Oncology Think Tank, initiated by Prof. Azra
Press release : ISET® technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS
PARIS, April 6, 2021 /PRNewswire/ — Rarecells Inc., a leading Liquid Biopsy company is pleased to
Press release : ISET® test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells
We are enthusiastic to share the results of the Professor Karin Ried and researchers of
2nd Liquid Biopsies Congress – Global Exchange
Attend the Keynote presentation ”New non-invasive approaches for early diagnosis and follow up of
Press release : ISET® technology applied to DLA products from NSCLC patients identified more CTC than other systems
We are enthusiastic to share the results of the research conducted by Dr Tamminga